Plasma biomarkers in graft-versus-host disease: a new era?

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Sophie PaczesnyJames L M Ferrara

Abstract

Acute graft versus host disease (GVHD) remains a major complication of allogeneic hematopoietic cell transplantation (HCT). The diagnosis of acute GVHD is based on strictly clinical criteria and its severity also determined by these criteria. Currently, there is no validated diagnostic blood test for acute GVHD. This review will summarize proteomics approaches to identify biomarkers for GVHD in the plasma with diagnostic, prognostic and predictive value. If successful, these studies could establish a novel biomarker panel that will contribute important information including long term survival, and that may eventually facilitate therapeutic decisions for allogeneic HCT patients.

References

Mar 7, 1991·The New England Journal of Medicine·J L Ferrara, H J Deeg
Dec 24, 1997·Bone Marrow Transplantation·H GondoY Niho
Nov 3, 1998·Transplantation·L M LiemE Goulmy
Aug 18, 2001·Bone Marrow Transplantation·T OkamotoE Kakishita
Jul 29, 2003·Transplantation·Carina SeidelMats Remberger
Oct 31, 2003·Experimental Hematology·Jeane Eliete Laguila VisentainerCármino Antonio de Souza
May 27, 2006·Experimental Hematology·Ramaprasad SrinivasanRichard W Childs
Oct 13, 2006·Molecular & Cellular Proteomics : MCP·Hui ZhangRuedi Aebersold
Aug 19, 2007·Journal of Proteome Research·Vitor FacaSamir Hanash
Oct 4, 2008·Blood·Sophie PaczesnyJames L M Ferrara
May 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fabrizio Carnevale-SchiancaRichard A Nash
Sep 30, 2014·Bone Marrow Transplantation·N RandallC Ustun

❮ Previous
Next ❯

Citations

Aug 7, 2012·Bone Marrow Transplantation·Y-B Chen, C S Cutler
Mar 8, 2011·Omics : a Journal of Integrative Biology·Sam Hanash
Apr 16, 2014·Mediators of Inflammation·Florent Malard, Mohamad Mohty
Oct 9, 2009·Current Opinion in Hematology·Sophie PaczesnyJames L M Ferrara
Nov 10, 2015·Bone Marrow Transplantation·S G Holtan, M L MacMillan
Sep 20, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lenneke F J van GroningenWalter J F M van der Velden
Dec 24, 2010·Vox Sanguinis·D V Devine, P Schubert
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Frédéric Baron, Rainer Storb
Mar 27, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrizia ChiusoloMassimo Castagnola
May 21, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Holbrook E KohrtRobert Lowsky
Jun 27, 2017·Bone Marrow Transplantation·E MirM Diaz-Ricart
Oct 12, 2018·Proteomics. Clinical Applications·Sophie Paczesny, Jochen Metzger
Apr 2, 2020·Expert Review of Proteomics·Eva M WeissingerArnold Ganser
Aug 29, 2012·Proteomics. Clinical Applications·Gabriela LochmanováZbyněk Zdráhal
Jan 1, 2019·International Journal of Bone Marrow Research·Yvonne A EfeberaRamiro Garzon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2021 Meta ULC. All rights reserved